New Data: Perinatal MDD Peaks 2 Weeks After Birth

Published Date: 19 May 2026

The rate of major depressive disorder is roughly 6% during pregnancy and 7% during the postpartum period, peaking at about 2 weeks after birth, new research shows.

Read Full News

Latest News

White House Says It Will Send $500 Obamacare Refunds to Nearly a Million Americans

The White House said on Thursday it will send $500 to nearly one million Americans in 30 states who are enrolled in Obamacare health insurance plans, payments it described...

Disparities in Urban and Rural Mortality from Non-Melanoma Skin Cancers

This study assessed differences in age-adjusted mortality rates in nonmelanoma skin cancer in U.S. urban and rural populations.

Improving Resident Attitudes Toward Patients with SCA

This study evaluated whether a CAB-designed educational intervention could improve resident physician attitudes toward patients with SCA.

Does This New Clue Explain the Smoking-Parkinson’s Mystery?

Carbon monoxide may help explain the long-observed but perplexing association between smoking and a lower risk for Parkinson’s disease.

Cancer Screening Lower for Adults With Disabilities

A new study finds millions of adults with disabilities are missing critical cancer screenings, but those with disabilities have higher rates of at-home stool testing for colorectal cancer.

Early Remdesivir May Protect Kidney Grafts After COVID

Early antiviral intervention is associated with lower risks for graft loss and cardiovascular events in kidney transplant recipients with COVID.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Latest News

The White House said on Thursday it will send $500 to nearly one million Americans in 30 states who are enrolled in Obamacare health insurance plans, payments it described...

This study assessed differences in age-adjusted mortality rates in nonmelanoma skin cancer in U.S. urban and rural populations.

This study evaluated whether a CAB-designed educational intervention could improve resident physician attitudes toward patients with SCA.

Carbon monoxide may help explain the long-observed but perplexing association between smoking and a lower risk for Parkinson’s disease.

A new study finds millions of adults with disabilities are missing critical cancer screenings, but those with disabilities have higher rates of at-home stool testing for colorectal cancer.

Early antiviral intervention is associated with lower risks for graft loss and cardiovascular events in kidney transplant recipients with COVID.

News All Time

Low-Dose Sq Decitabine ± Venetoclax in Myeloid Malignancies

Across 4 VA sites, 22 veterans with AML, MDS, or CMML tolerated low-dose sq decitabine±venetoclax, showing feasibility in a hard-to-treat population.

Tourette Syndrome: When Tics Change, Should Care Change?

Distinguishing typical tics from functional tic-like behaviors can be challenging, particularly with psychiatric comorbidities and changing symptom patterns.

Oestrogen Therapy Improves Prolapse Surgery Outcomes

Vaginal oestrogen therapy initiated before prolapse surgery improves prolapse symptoms and quality of life in postmenopausal women at 12 months.

Retaining Medical Talent: Why Do Physicians Leave?

Healthcare organizations are reassessing how leadership, professional growth, work-life balance, and opportunities for teaching and research shape physicians’ career decisions.

Fiber Supplementation May Improve Clinical Response in IBS

Fiber supplementation may improve clinical response in adults with irritable bowel syndrome, with psyllium showing a greater clinical response than placebo, a meta-analysis shows.

Colchicine Shows No Benefit Over Placebo in Knee OA Pain

Patients with knee osteoarthritis who receive daily colchicine show no difference in knee pain reduction compared with those on placebo.

FDA Approves Stelara for Pediatric Ulcerative Colitis

Ustekinumab, the IL-12/23 inhibitor, is the first non-TNF-targeting monoclonal antibody approved for both pediatric UC and Crohn's disease.

Proteinuria Remission Predicts Outcomes in Pediatric IgAN

Children with IgA nephropathy who achieve sustained proteinuria remission have significantly better long-term kidney function over 5 years than those who do not.

Digital Pillbox Boosts Short-Term Viral Control in Young PWH

A digital pillbox with medication reminders and adherence feedback improves viral suppression in young people with HIV over 6 months, a trial finds.

Ketamine Infusions Shows Benefit in Bipolar Depression

Adjunctive serial IV ketamine infusions significantly reduced depressive symptoms in TRBD, with no cases of mania, hypomania, or psychosis observed in the randomized trial.

Once-Nightly Eye Drop Aids Dim-Light Vision

In patients who face difficulty seeing in low light, a once-nightly eye drop significantly improves night vision and reduces glare, halos, and starbursts, a phase 3 trial shows.

BRCA Mutation Carriers Likely to Have Risk-Reducing Surgery

Researchers conduct a study of about 4000 women with pathogenic variants in at least one of 13 breast cancer susceptibility genes to see their utilization of cancer risk-reducing procedures.

Distinct Risk Factor Profiles Tied to Endometriosis Subtypes

Various factors such as menstrual history, pain conditions, and immune disorders are distinctly tied to endometriosis lesion types — superficial lesions, ovarian cysts, and deep lesions.
HTTP error: 503

A Public Utility Model for Primary Care?

As more struggling practices turn to private equity, Dr Kenny Lin asks who benefits — and whether a public utility model offers a workable alternative.
HTTP error: 503

Recommended News For You

Recommended Articles For You

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot